[The effect of selective bowel decontamination and mechanical bowel preparation on bacterial translocation due to intraabdominal hypertension].
BACKGROUND
The objective of our study is to evaluate the preventive effects of selective digestive decontamination (SDD) and mechanical bowel preparation in rats with experimentally induced bacterial translocation.


METHODS
Fourty adult male Sprague Dowley rats weighing 250-300 g. were divided equally into four groups as Group 1 (sham [control]), Group 2 (experimentally induced IAH at 19 mmHg), Group 3 ( SDD group) and Group 4 (SDD and mechanical bowel preparation with 19 mmHg intraabdominal pressure). Group 3 and 4 were treated at 12 hours intervals with oral gentamycine 5 mg/kg and IM sefotaxime 100mg/kg Mechanical bowel preparation was performed by oral administration of sodium phosphate. After 24 hours all rats were sacrified; mesenteric lymph nodes, spleen and liver biopsy specimens were harvested aseptically. Specimens were diluted and cultured in McConkey medium and the colony-forming units (CFU/gr ) were calculated.


RESULTS
In Kruskal Wallis tests there were no significant differences between Group 1 and 3 or 4, and also Group 3 and 4 (p>0.05, p=0.872 respectively), while differences between Group 1 and 2, and also Group 3 and 4 were statistically significant (p<0.001) with respect to CFU/g estimates.


CONCLUSIONS
These data indicate that selective intestinal decontamination and mechanical bowel preparation prevent bacterial translocation due to intraabdominal hypertension.
Gönüllü
Doğan
D
Taksim Training and Research Hospital, 2. Clinics of Surgery, Istanbul, Turkey. dogangonullu@yahoo.com
Ceylan
Ahmet
A
Demiray
Okan
O
Erpek Uzümcü
Meltem
M
Köksoy
Ferda Nihat
FN
Yücel
Osman
O
D000150:Acinetobacter / Q000502:physiology; D000818:Animals; D018988:Bacterial Translocation; D015169:Colony Count, Microbial; D003161:Compartment Syndromes / Q000517:prevention & control*; D004926:Escherichia coli / Q000502:physiology; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005839:Gentamicins / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000382:microbiology; D008198:Lymph Nodes / Q000187:drug effects / Q000382:microbiology; D008297:Male; D008643:Mesentery / Q000187:drug effects* / Q000382:microbiology; D011511:Proteus / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000187:drug effects / Q000382:microbiology; D013211:Staphylococcus aureus / Q000502:physiology; D013392:Sucralfate / Q000494:pharmacology* / Q000627:therapeutic use
D005765:Gastrointestinal Agents; D005839:Gentamicins; D013392:Sucralfate